Ä¢¹½´«Ã½

Support

Country Websites

Acute Care Cartridges

Acute care cartridges for Kidney Replacement Therapy (KRT) and Therapeutic Plasma Exchange (TPE).

NxStage disposable cartridges for acute care remove toxins effectively with the simplicity and flexibility you need for your patients and staff.

Multi-functional design with a broad range of flow rates allows you to prescribe the therapy that is best for your patient

  • Easily switch between CVVH, CVVHD, SHIFT, or SCUF treatments


Volumetric fluid balancing achieves fluid accuracy without the need for scales, and eliminates scale-based alarms

  • Elimination of waste bag changes reduces therapy interruptions
    • No waste bags
    • No waste bag changes
    • No splash and injury risk from waste bag changes
    • No scale-related alarms
  • Direct-to-drain effluent disposal may decrease workload and allow the nurse more time to spend with patients.1


Specifically designed to eliminate blood-air interface which may reduce the risk of filter clotting and extend filter life2

  • Extending filter life may help achieve
    • Treatment efficiencies
    • Reduced expense
    • Less demand on nursing time for replacing the circuit3


Fully integrated cartridges incorporate all fluid circuits

  • Reduced cost and workload associated with cycler maintenance and disinfection requirements as compared with conventional hemodialysis equipment


Multi-line adapters simplify fluid management

  • Ability to hang up to 29 liters at once eliminating frequent bag changes

TPE Cartridge - CAR-510

The NxStage TPE cartridge with Asahi PlasmafloTM OP-05W(A) Plasma Separator is designed to provide:

Safety

  • Low extracorporeal blood volume (110 mL) minimizes the risk of blood loss
  • Gamma sterilized filter and circuit eliminate the risk of reaction to residual ETO (ethylene oxide)


Effectiveness

  • Fast treatment time with up to 4.0 L of plasma exchange per hour may offer flexibility in scheduling treatments
  • Allows you to use one simple system for RRT and TPE


Convenience

  • Up to nine connections for replacement fluid
  • Less training time may be required with more frequent use of the System One and a similar drop-in cartridge4


NxStage TPE Cartridge with ASAHI PLASMAFLOâ„¢ÌýOP-05W(A) Plasma Separator


Permeability to plasma components6
 Figure shows the in vivo permeability of the OP-05W to various plasma components up to 3 liters of plasma perfusion volume.

With a 0.5m2Ìýsurface area and 0.3 micron pore size, the filter is designed to offer:

  • High clearance of plasma proteins
  • Minimal loss of cellular components


"Nephrologists are well trained in the management of extracorporeal blood purification and the ability to do TPE with the NxStage system made the transition easy. Our nurses are already familiar with the NxStage system and are comfortable with membrane-based technology."

Ä¢¹½´«Ã½” Dr. Casey Gashti, Assistant Professor of Nephrology,
Rush University Medical Center, Chicago, IL


Risks
Therapeutic plasma exchange and renal replacement therapy, like any medical therapies, are not without risks. The decision of which therapy to use should be made by the physician, based on previous experience and on the individual facts and circumstances of the patient.

For more information on the Acute Care Cartridges, call NxStage at 1-866-NXSTAGE (697-8243) or fill out the form to speak with an expert.

Ìý

Cartridge Express - CAR-505

Designed with enhanced safety features

Ìý

SecureClip®Ìýaccess tubing connector

  • Pre-attached to the arterial and venous lines
  • Designed to reduce the risk of access tubing disconnects
  • Easy to use5

Needleless Valves are designed for easy, on-demand aspiration or injection of fluids

  • The valve maintains its microbial barrier properties based on test results of 140 activations over a 7-day period, when used with an adequate disinfection procedure.7
  • Designed to minimize the incidence of air in the circuit.
  • Complies with needle-free policies and legislation.8

Cartridge Express with Extended Tubing - CAR-502

Additional 4.5 feet of blood line tubing provides extreme flexibility in placing equipment, particularly in a crowded environment.

Ìý

Low-volume Cartridge - CAR-125
Ìý

The CAR-125 low-volume cartridge is designed for use on patients when low extracorporeal volume is required.

The specifically designed small diameter tubing, along with the RenafloÌýII low-volume filter and volumetric fluid balancing system, can be used to deliver renal replacement therapy safely, accurately and conveniently with 83 mL total extracorporeal blood volume.

TPE Cartridge - CAR-510

The Purema H Membrane is a high-efficiency polyethersulfone membrane with a large 1.6m2Ìýsurface area designed with Performance Enhancing Technology (PET). PET spacer yarns consist of multifilament threads that are integrated into the fiber bundles, which results in:

  • Improved dialysate distribution throughout the filter, which is designed to increase clearance and maintain consistent performance clearance values throughout the dialysis treatment9-11
  • Achieve high clearances of small and middle molecular toxins with simultaneous retention of valuable proteins, ie, albumin
  • Gamma sterilized and manufactured from glycerin-free polyethersulfone membranes (PUREMA H), known for biocompatibility9

No flushing required during prime due to the biocompatible materials and processes used in its manufacture and sterilization.8

These products may not be available in all countries.

Related Pages

THE NXSTAGE® SYSTEM ONE™ S WITH NXVIEW™

Improving the SIMPLICITY of acute renal replacement therapy.

PUREFLOWâ„¢ BICARBONATE SOLUTION

PureFlow Bicarbonate Solutions can help correct and manage acidosis and reduce potential risks of compounding errors.

Risk Information:

Kidney replacement therapy, as with any medical therapy, is not without risks. The decision of which therapy to use should be made by the physician, based on previous experience and on the individual facts and circumstances of the patient. There is no literature demonstrating one therapy is clinically better than another.13ÌýNxView is contraindicted as the sole method of monitoring a patient during treatment.14


Caution:ÌýFederal law restricts this device to sale by or on the order of a physician.


References

  1. Gashti CN, MD, Rodby RA, et al. Accelerated Venovenous Hemofiltration: Early Technical and Clinical Experience. American Journal of Kidney Diseases, 2008.
  2. Polaschegg HD. The extracorporeal circuit. Semin Dial. 1995;8(5):299-304.
  3. Davies H, et al. Maintaining the CRRT Circuit; non-anticoagulant alternatives. Australian Critical Care. 06;19(4).
  4. NxView User Guide. NC23088 Rev. C 2022-03.
  5. NxStage CAR-505 IFUm NC45-0293 Rev. E 2021-07.
  6. Nagano T et al. Jpn J Apheresis 16(1): 297-298, 1997.
  7. Robertsite 7-day Microbial Challenge Evaluation, P Miller, December 2007. Halkey-Roberts Corporation.
  8. Needlestick Prevention and Safety Act, 106th Congress, Public Law 106-430, 2000.
  9. Data on File. Membrana, Wuppertal, Germany www.membrana.com
  10. Krieter DH, Morgenroth A, Barasinski A, et al. Effects of a polyelectrolyte additive on the selective dialysis membrane permeability for low-molecular-weight proteins. Nephrol Dial Transplant. 2007;22(2):491-499.
  11. Bodo von Harten-Membrana GmbH, Wuppertal, Germany Webinars. Membranes and filters for renal replacement therapies part 1 and part II. Posted on www.NxStage.com.
  12. Kraus MA. Selection of Dialysate and Replacement Fluids and Management of Electrolyte and Acid-Base Disturbances. Seminars in Dialysis; Vol 22, No 2 (MarchÄ¢¹½´«Ã½“April) 2009 pp. 137Ä¢¹½´«Ã½“140.
  13. Nash DM, Przech S, Wald R, OÄ¢¹½´«Ã½™Reilly D. Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit. J Crit Care 2017 41:138-144.
  14. NxStage System One Critical Care User Guide. NC4921 Rev. M. 2022.

Ìý

© 2024 Ä¢¹½´«Ã½. All Rights Reserved. Ä¢¹½´«Ã½, the triangle logo, NxStage, NxView, and System One are trademarks of Ä¢¹½´«Ã½ Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners.

APM2160 Rev. E

Contact

Country Websites

All Contact Information

Social Media

© 2006-2025 Ä¢¹½´«Ã½. All Rights Reserved.

Privacy Statement

Terms of Use